What Metronidazol Actavis Treats: Main Uses and Benefits

Metronidazol Actavis is commonly used for conditions caused by specific anaerobic bacteria and protozoal parasites, applied in contexts that involve acute or disruptive symptom patterns. The key therapeutic domains involve addressing systemic and localized discomfort and supporting the general well-being during symptomatic phases. As an anti-infective agent, metronidazole is indicated for infections across various body systems.

---

Therapeutic Coverage and Patient Support

The medication is commonly used across conditions presenting with acute episodes, such as intra-abdominal abscesses, sepsis, and gynecological infections, and parasitic diseases like Amebiasis, Giardiasis, and Trichomoniasis. It is also commonly used in surgical prophylaxis to address anticipated anaerobic bacteria.

The medication is used to help with symptoms related to systemic imbalance (like high fever and malaise) and physical discomfort (such as protracted diarrhea and cramping). This therapeutic focus is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.

“The benefit supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms become more noticeable.”

Quick Fact: Relief for Gastrointestinal and Systemic Discomfort The drug is used for managing symptoms related to organ-specific functional stress caused by specific parasitic infections of the gut, or bacterial infections leading to systemic distress.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility Profile

Metronidazol Actavis is subject to strict eligibility rules based on authoritative regulatory documentation. Use is contraindicated (must not be used) for the following populations:

• Patients with a known hypersensitivity to metronidazole or any other nitroimidazole medicine.
• Individuals diagnosed with Cockayne syndrome, due to the severe and potentially fatal risk of liver failure.
• Patients who have taken disulfiram (Antabuse) within the last two weeks (14 days).
• Women during the first trimester of pregnancy.

Conditional and Restricted Use

Specific populations are eligible only under strict caution and monitoring:

• Severe Hepatic Impairment: Requires a mandatory dose reduction (e.g., 50% decrease) due to slower drug metabolism.
• Active CNS Disease: Use is restricted; treatment must be discontinued if neurological symptoms occur.
• Blood Dyscrasia: Caution is advised, and monitoring of blood counts is recommended.

Age and Physiological Limitations

• Pediatric Use: Safety and efficacy are not established for most indications, except for the treatment of amebiasis.
• Breastfeeding: Use is generally not recommended, or cessation of breastfeeding for a defined period (e.g., 48 hours) may be required after a single high-dose treatment.

Interactions with other medicines and products

The interaction profile of Metronidazol Actavis is defined by specific combinations that are either strictly prohibited or require close monitoring, as established by regulatory authorities.

---

Officially Contraindicated Combinations

Co-administration is strictly prohibited in the following cases:

Interacting Agent	Regulatory Restriction
Disulfiram	Must not be administered within two weeks of Metronidazole due to the risk of psychotic reactions.
Alcohol (Ethanol)	Must be avoided during treatment and for at least three days (72 hours) after stopping Metronidazole due to the risk of a disulfiram-like reaction.
Propylene Glycol	Avoid products containing this substance for at least three days post-treatment, similarly due to disulfiram-like reaction risk.

---

Documented Pharmacokinetic Interactions

Metronidazole can alter the plasma levels of certain co-administered drugs or be altered by them:

• Oral Anticoagulants (e.g., Warfarin): Metronidazole is documented to potentiate the anticoagulant effect, requiring monitoring of prothrombin time and INR.
• Lithium: Co-administration can increase serum Lithium concentrations, necessitating careful monitoring of serum levels.
• Busulfan: Metronidazole may increase busulfan plasma levels, raising the risk of toxicity.
• Enzyme Inducers/Inhibitors: Medicines like Phenytoin and Phenobarbital can accelerate the metabolism of Metronidazole (reducing its half-life), while Cimetidine can reduce its clearance, potentially increasing its plasma concentration.

---

Population-Specific Notes

Official labeling advises caution in patients with severe hepatic impairment and End-Stage Renal Disease (ESRD), as the accumulation of Metronidazole and its metabolites is documented in these populations.

Selective Reductive Activation by Anaerobic Enzymes

Metronidazole functions as an inactive prodrug that requires a unique chemical conversion to become active. This conversion, called reductive activation, is only possible inside specific target microbes (anaerobic bacteria and protozoa) that possess specialized low-potential electron transfer proteins, such as nitroreductase enzymes . This selective reliance confines the reductive activation to anaerobic environments, thereby restricting the formation of the toxic radical to the target microbe.

---

Targeted DNA Disruption and Cell Destruction

Once activated into a highly reactive nitro radical intermediate, the drug executes its primary action by attacking and binding to the microbe's DNA. This attack causes irreversible fragmentation and strand breakage, completely disrupting the cell's genetic integrity and preventing critical functions like replication and repair. This cytotoxic effect is bactericidal (cell-killing), resulting in the definitive destruction of the target microbial cell.

---

Mechanistic Constraint by Oxygen

The drug's mechanism is intrinsically constrained by the presence of molecular oxygen (O2), which chemically competes for the same activating electrons needed to convert the prodrug into the toxic radical. This dependency on electron competition dictates the lack of activity against aerobic organisms and limits the mechanism's functional relevance to low-oxygen environments.

How Metronidazol Actavis is Used: Official Administration Guidelines

Metronidazol Actavis, whose active substance is metronidazole, must be administered according to specific instructions that vary by dosage form and route.

Official Dosing and Routes

The medicine is approved for oral (tablets, capsules, suspension), intravenous (IV) infusion, and topical/vaginal administration. Systemic use often begins with the IV route for serious infections, followed by a switch to oral therapy.

Regimen Example	Dose and Frequency (Adult)	Duration Pattern
Anaerobic Infections	Initial IV loading dose of 15 mg/kg, followed by 7.5 mg/kg maintenance every 6 hours (Q6h) (Max 4 g/day)	Typically 7 to 10 days
Amebiasis	750 mg orally three times daily (TID)	5 to 10 days
Surgical Prophylaxis (IV)	15 mg/kg pre-operation, with post-operative 7.5 mg/kg doses	Discontinued within 12 hours after surgery

---

Special Administration Conditions

• Timing with Food: Immediate-release oral forms can be taken with or without food. Extended-release tablets must be administered on an empty stomach (1 hour before or 2 hours after meals).
• IV Administration: Intravenous solutions must be infused slowly, typically over 30 to 60 minutes.
• Dose Adjustment: A 50% dosage reduction is recommended in patients with severe hepatic impairment (Child-Pugh C) due to slow metabolism. Supplementary doses may be considered for patients following hemodialysis.
• Pediatric Dosing: Dosing for children is based on body weight (mg/kg) and is usually divided into three daily doses.

Research Evidence / Overview of Studies for Metronidazol Actavis

The research base for Metronidazol Actavis is compiled from various clinical studies, including randomized controlled trials and large-scale reviews, spanning several decades. This overview describes the kinds of research that have been conducted for its licensed uses and where the scientific evidence notes limitations or uncertainty.

---

Evidence for Use in Treating Systemic and Surgical Anaerobic Infections

The research base for Metronidazol Actavis in treating serious systemic infections, such as abscesses or infections related to surgical procedures, is documented. This evidence draws from existing Randomized Controlled Trials (RCTs) and high-level Regulatory Reviews.

Studies monitored outcomes related to systemic or functional imbalance, primarily measuring clinical resolution (e.g., clearance of fever) and microbiological eradication, which refers to the elimination of the target bacteria. Research also explored the prophylactic role of the medicine, meaning its use in studies focused on infection avoidance before or during surgery.

Findings describe patterns observed in the studies that were reported across many severe anaerobic infections. Results apply only to the populations studied; comparative evidence against the newest antimicrobial agents in all specific sub-infections is often limited.

---

Evidence for Use in Treating Parasitic Infections and Localized Conditions

The medicine was studied for its use against specific single-celled parasites, including Trichomoniasis and Amebiasis. For these conditions, research primarily measured parasitological cure (the elimination of the parasite) and examined outcomes related to physical discomfort. Research provides insight into short-term changes during the acute phase of the disease, but long-term effects are not fully established.

For Bacterial Vaginosis (BV), studies examined both oral tablets and topical gels, measuring clinical cure based on diagnostic criteria. Studies contribute to the broader evidence landscape regarding short-term changes observed in the study populations, but research highlights that a high rate of recurrence was observed in some studies.

---

Research Gaps and What Remains Uncertain

Data for certain groups remain insufficient, meaning subgroup findings are uncertain for some populations, such as those with organ impairment. The evidence base largely consists of research that explored short-term symptom changes, with follow-up durations limited to the time necessary for acute measurement. Comparative evidence is lacking in some areas, and evidence for long-term outcomes is not fully established.

Key Studies & References Metronidazole: MedlinePlus Drug Information (NIH)

Common questions about Metronidazol Actavis (FAQ)

---

Q: What kind of infections is Metronidazol Actavis for?

A: The medicine is indicated for treating infections caused by specific types of susceptible microbes. This includes infections caused by anaerobic bacteria and infections caused by certain protozoa, which are single-celled parasites.

Q: Does Metronidazol Actavis treat fungal infections?

A: Metronidazol Actavis is classified as an antimicrobial agent primarily active against certain anaerobic bacteria and protozoa. Regulatory documents state that it is not indicated for treating fungal infections.

Q: What is the difference between Metronidazol Actavis and penicillin?

A: The medicine belongs to the nitroimidazole class of antimicrobial agents. This is a pharmacological classification that is distinct from the penicillin class of antibiotics.

Q: How quickly does Metronidazol Actavis start working?

A: Official product information indicates that the active ingredient is rapidly absorbed into the body, typically within one to two hours. However, the actual clinical improvement of symptoms may require a few days of continued treatment.

Q: What is the usual duration of treatment with this medicine?

A: The duration of use is specific to the type of infection being treated, as defined in regulatory documents. Courses can range from a single dose for some conditions to a typical 7 to 10 days, or occasionally longer for severe infections.

Q: Can I take Metronidazol Actavis with food?

A: Immediate-release oral forms of the medicine can be administered with or without food. However, extended-release formulations are typically advised to be taken on an empty stomach to ensure proper function.

Q: Can I stop taking Metronidazol Actavis once I feel better?

A: Official guidance emphasizes that the full prescribed course of medicine should be completed. The full prescribed course of medicine is advised, as premature cessation is associated with a potential for the infection to return.

Q: What happens if I miss a dose of Metronidazol Actavis?

A: If a dose is forgotten, the official guidance is to take it as soon as you remember. However, if it is almost time for your next scheduled dose, the missed dose should be skipped entirely. Skipping the dose in this circumstance is the official guidance.

Q: Is it normal to feel sick to my stomach after taking Metronidazol Actavis?

A: Nausea and other disturbances in the stomach and digestive system are officially classified as common side effects of this medicine. This means they are frequently reported in the safety profile.

Q: Is dizziness a side effect of Metronidazol Actavis?

A: According to the official product information, dizziness or lightheadedness are documented as commonly reported side effects. These effects are typically noted in the safety documentation.

Q: Can Metronidazol Actavis affect my sleep?

A: Trouble sleeping or insomnia has been noted among the documented side effects of this medicine in official reports.

Q: Does Metronidazol Actavis cause long-term side effects?

A: Rare, serious side effects have been documented in official product labeling, particularly with prolonged use. These include nerve issues called peripheral neuropathy.

Q: Is Metronidazol Actavis known to cause nerve issues?

A: Rare but serious effects on the nervous system are officially documented. These include peripheral neuropathy (damage to nerves in the hands and feet), convulsions, and encephalopathy (a condition affecting the brain).

Q: Does Metronidazol Actavis interact with pain relievers like ibuprofen?

A: Official regulatory documents list specific medicines and agents that are strictly prohibited during treatment. Common pain relievers, such as ibuprofen, are generally not listed among these strictly prohibited drug combinations.

Q: How does Metronidazol Actavis interact with lithium?

A: Official interaction documents state that co-administration of this medicine is documented to increase serum concentrations of Lithium. Because of this effect, careful monitoring of the patient’s serum Lithium levels is required during treatment.

Q: Is Metronidazol Actavis safe for older people?

A: Official labeling notes that older adults may process the medicine more slowly than younger individuals. This can potentially lead to higher levels of the drug in the body, which may increase the risk of side effects.

Q: Can children use Metronidazol Actavis?

A: The safety and efficacy are not fully established for most conditions when used in children. However, official documents confirm its use for the treatment of amebiasis in the pediatric population, where dosing is calculated based on body weight.

Q: Is Metronidazol Actavis safe during pregnancy?

A: The medicine is officially contraindicated during the first trimester of pregnancy. For the second and third trimesters, official guidelines state that a careful risk/benefit assessment is required, as adequate, well-controlled human studies have not been conducted.

Q: Why is Metronidazol Actavis used for dental infections?

A: Metronidazole is indicated for the treatment of certain susceptible infections in the oral and periodontal (gum) areas. These infections are often caused by the type of anaerobic bacteria that the medicine is designed to target.

Q: Is Metronidazol Actavis effective against H. pylori?

A: The medicine is listed in professional guidelines as part of combination therapy regimens (e.g., triple or quadruple therapy). This combination approach is used for the eradication of Helicobacter pylori infection.

Q: Are there specific tests needed before starting Metronidazol Actavis?

A: Official guidance advises that monitoring of blood counts may be recommended during or after treatment, especially for patients with a history of a blood disorder (blood dyscrasia).

Q: Is it true that Metronidazol Actavis can affect my blood test results?

A: The active ingredient is documented to interfere with the results of certain laboratory tests. This includes tests for liver enzymes and triglycerides, which can potentially lead to values that appear inaccurate.

Q: What does 'anaerobic bacteria' mean in simple terms?

A: Anaerobic bacteria are a specific type of germ that is able to live and grow in environments where there is very little or no oxygen. The medicine is specifically designed to target and eliminate these types of microbes.

Q: Is the 'Actavis' part of the name important?

A: The name 'Actavis' refers to the company that manufactures and markets this specific pharmaceutical product. The active ingredient within the medicine is metronidazole.

Q: Does Metronidazol Actavis treat parasites?

A: Yes, in addition to targeting anaerobic bacteria, the medicine is indicated for treating certain infections caused by protozoa. Protozoa are a type of single-celled parasite.

Q: Can Metronidazol Actavis be used for skin infections?

A: Yes, the topical formulations of the medicine are indicated for the treatment of certain skin conditions. This includes conditions like rosacea and for managing infected ulcers or wounds.

Q: Is there evidence that Metronidazol Actavis causes changes in mood?

A: Official documents list rare effects on the central nervous system. These can include confusion, psychotic disorders, and reports of mood changes such as depression or irritability.

Q: What kind of studies support the use of Metronidazol Actavis?

A: The clinical use of the medicine is supported by evidence from various studies, as cited in regulatory documents. This includes data derived from Randomized Controlled Trials (RCTs) and comprehensive regulatory reviews.

Q: Does Metronidazol Actavis contain lactose or gluten?

A: The specific inactive ingredients, or excipients, vary depending on the dosage form (tablet, liquid, etc.) and the manufacturer. This detailed information can be found in the official Patient Information Leaflet or the Summary of Product Characteristics (SmPC) for the specific product received.

Storage and Disposal Requirements

The required conditions for storing Metronidazole are established by regulatory labeling to maintain product stability and integrity.

Metronidazole must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with protection from temperature excursions. Both the tablets and the injection solution must be protected from light, and the injection solution must also be protected from freezing.

Container and Safety

Oral forms must be dispensed in a tight, light-resistant container equipped with a child-resistant closure. All forms must be kept out of the sight and reach of children.

Disposal

For disposal, any unused portion of a single-dose container must be discarded. Unused or expired medication should not be placed in household trash or wastewater and must be disposed of according to local regulatory requirements, such as drug take-back programs.